Cargando…
Programmed death ligand 1, poly adenosine diphosphate ribose polymerase, and vascular endothelial growth factor receptor inhibition: a potential combination regimen for targeting triple-negative breast cancer?
Autores principales: | Abdul Wahid, Maryam, Hussain, Hassan ul, Ghouri, Hafsa, Khan, Tarneem, Rehan, Syeda Tayyaba, Mumtaz, Hassan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583937/ https://www.ncbi.nlm.nih.gov/pubmed/37352527 http://dx.doi.org/10.1097/JS9.0000000000000550 |
Ejemplares similares
-
Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors in Pancreatic Cancer
por: Sunkara, Tejasvi, et al.
Publicado: (2022) -
Expression of Poly(Adenosine Diphosphate-Ribose) Polymerase Protein in Breast Cancer
por: Akanksha,, et al.
Publicado: (2022) -
Do Not Forget Poly (Adenosine Diphosphate-Ribose) Polymerase Inhibitors in Ovarian Carcinosarcoma
por: Magalhães, Denise, et al.
Publicado: (2022) -
Strategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy
por: Ström, Cecilia E., et al.
Publicado: (2012) -
Role of Poly Adenosine Diphosphate Ribose Polymerase Inhibitors in Advanced Stage Ovarian Cancer
por: Arora, Ena, et al.
Publicado: (2018)